Richard J Miron1, Vittorio Moraschini2, Masako Fujioka-Kobayashi3, Yufeng Zhang4, Tomoyuki Kawase5, Raluca Cosgarea6, Soren Jepsen7, Mark Bishara8, Luigi Canullo9, Yoshinori Shirakata10, Reinhard Gruber11, Döri Ferenc12, Monica Diuana Calasans-Maia13, Hom-Lay Wang14,15, Anton Sculean14. 1. Department of Periodontology, University of Bern, Bern, Switzerland. richard.miron@zmk.unibe.ch. 2. Department of Periodontology, Dental Research Division, School of Dentistry, Veiga de Almeida University, Rio de Janeiro, Brazil. 3. Department of Cranio-Maxillofacial Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 4. Department of Oral Implantology, University of Wuhan, Wuhan, China. 5. Division of Oral Bioengineering, Institute of Medicine and Dentistry, Niigata University, Niigata, Japan. 6. Department of Prosthetic Dentistry, University Iuliu Hatieganu, Cluj-Napoca, Romania. 7. Department of Periodontology, Operative and Preventive Dentistry, University of Bonn, Bonn, Germany. 8. Division Private practice, West Bowmanville Family Dental, Bowmanville, Ontario, Canada. 9. Independent researcher, Rome, Italy. 10. Department of Periodontology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 11. Department of Oral Biology, University of Vienna, Vienna, Austria. 12. Department of Periodontology, Semmelweis University, Budapest, Hungary. 13. Department of Oral Surgery, School of Dentistry, Fluminense Federal University, Rua Mario dos Santos Braga, 30, Centro, Niteroi, Rio de Janeiro, Brazil. 14. Department of Periodontology, University of Bern, Bern, Switzerland. 15. Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
OBJECTIVES: This study aims to compare the treatment outcomes of periodontal intrabony defects by using platelet-rich fibrin (PRF) with other commonly utilized modalities. MATERIALS AND METHODS: The eligibility criteria comprised randomized controlled trials (RCTs) comparing the clinical outcomes of PRF with that of other modalities. Studies were classified into 10 categories as follows: (1) open flap debridement (OFD) alone versus OFD/PRF; (2) OFD/bone graft (OFD/BG) versus OFD/PRF; (3) OFD/BG versus OFD/BG/PRF; (4-6) OFD/barrier membrane (BM), OFD/PRP, or OFD/enamel matrix derivative (EMD) versus OFD/PRF; (7) OFD/EMD versus OFD/EMD/PRF; (8-10) OFD/PRF versus OFD/PRF/metformin, OFD/PRF/bisphosphonates, or OFD/PRF/statins. Weighted means and forest plots were calculated for probing depth (PD), clinical attachment level (CAL), and radiographic bone fill (RBF). RESULTS: From 551 articles identified, 27 RCTs were included. The use of OFD/PRF statistically significantly reduced PD and improved CAL and RBF when compared to OFD. No clinically significant differences were reported when OFD/BG was compared to OFD/PRF. The addition of PRF to OFD/BG led to significant improvements in CAL and RBF. No differences were reported between any of the following groups (OFD/BM, OFD/PRP, and OFD/EMD) when compared to OFD/PRF. No improvements were also reported when PRF was added to OFD/EMD. The addition of all three of the following biomolecules (metformin, bisphosphonates, and statins) to OFD/PRF led to statistically significant improvements of PD, CAL, and RBF. CONCLUSIONS: The use of PRF significantly improved clinical outcomes in intrabony defects when compared to OFD alone with similar levels being observed between OFD/BG and OFD/PRF. Future research geared toward better understanding potential ways to enhance the regenerative properties of PRF with various small biomolecules may prove valuable for future clinical applications. Future research investigating PRF at histological level is also needed. CLINICAL RELEVANCE: The use of PRF in conjunction with OFD statistically significantly improved PD, CAL, and RBF values, yielding to comparable outcomes to OFD/BG. The combination of PRF with bone grafts or small biomolecules may offer certain clinical advantages, thus warranting further investigations.
OBJECTIVES: This study aims to compare the treatment outcomes of periodontal intrabony defects by using platelet-rich fibrin (PRF) with other commonly utilized modalities. MATERIALS AND METHODS: The eligibility criteria comprised randomized controlled trials (RCTs) comparing the clinical outcomes of PRF with that of other modalities. Studies were classified into 10 categories as follows: (1) open flap debridement (OFD) alone versus OFD/PRF; (2) OFD/bone graft (OFD/BG) versus OFD/PRF; (3) OFD/BG versus OFD/BG/PRF; (4-6) OFD/barrier membrane (BM), OFD/PRP, or OFD/enamel matrix derivative (EMD) versus OFD/PRF; (7) OFD/EMD versus OFD/EMD/PRF; (8-10) OFD/PRF versus OFD/PRF/metformin, OFD/PRF/bisphosphonates, or OFD/PRF/statins. Weighted means and forest plots were calculated for probing depth (PD), clinical attachment level (CAL), and radiographic bone fill (RBF). RESULTS: From 551 articles identified, 27 RCTs were included. The use of OFD/PRF statistically significantly reduced PD and improved CAL and RBF when compared to OFD. No clinically significant differences were reported when OFD/BG was compared to OFD/PRF. The addition of PRF to OFD/BG led to significant improvements in CAL and RBF. No differences were reported between any of the following groups (OFD/BM, OFD/PRP, and OFD/EMD) when compared to OFD/PRF. No improvements were also reported when PRF was added to OFD/EMD. The addition of all three of the following biomolecules (metformin, bisphosphonates, and statins) to OFD/PRF led to statistically significant improvements of PD, CAL, and RBF. CONCLUSIONS: The use of PRF significantly improved clinical outcomes in intrabony defects when compared to OFD alone with similar levels being observed between OFD/BG and OFD/PRF. Future research geared toward better understanding potential ways to enhance the regenerative properties of PRF with various small biomolecules may prove valuable for future clinical applications. Future research investigating PRF at histological level is also needed. CLINICAL RELEVANCE: The use of PRF in conjunction with OFD statistically significantly improved PD, CAL, and RBF values, yielding to comparable outcomes to OFD/BG. The combination of PRF with bone grafts or small biomolecules may offer certain clinical advantages, thus warranting further investigations.
Authors: Richard J Miron; Giovanni Zucchelli; Michael A Pikos; Maurice Salama; Samuel Lee; Vincent Guillemette; Masako Fujioka-Kobayashi; Mark Bishara; Yufeng Zhang; Hom-Lay Wang; Fatiha Chandad; Cleopatra Nacopoulos; Alain Simonpieri; Alexandre Amir Aalam; Pietro Felice; Gilberto Sammartino; Shahram Ghanaati; Maria A Hernandez; Joseph Choukroun Journal: Clin Oral Investig Date: 2017-05-27 Impact factor: 3.573
Authors: Richard J Miron; Masako Fujioka-Kobayashi; Mark Bishara; Yufeng Zhang; Maria Hernandez; Joseph Choukroun Journal: Tissue Eng Part B Rev Date: 2016-10-10 Impact factor: 6.389
Authors: Shariq Najeeb; Zohaib Khurshid; Muhammad Atif Saleem Agwan; Shazia Akhbar Ansari; Muhammad Sohail Zafar; Jukka Pekka Matinlinna Journal: Tissue Eng Regen Med Date: 2017-09-13 Impact factor: 4.169
Authors: Emanuelle Stellet Lourenço; Carlos Fernando de Almeida Barros Mourão; Paulo Emílio Corrêa Leite; José Mauro Granjeiro; Mônica Diuana Calasans-Maia; Gutemberg Gomes Alves Journal: J Biomed Mater Res A Date: 2018-01-31 Impact factor: 4.396
Authors: Himanshu Ajwani; Sharath Shetty; Dharmarajan Gopalakrishnan; Rahul Kathariya; Anita Kulloli; R S Dolas; A R Pradeep Journal: J Int Oral Health Date: 2015-04
Authors: Muhammad Syafiq Alauddin; Nur Ayman Abdul Hayei; Muhammad Annurdin Sabarudin; Nor Haliza Mat Baharin Journal: Membranes (Basel) Date: 2022-04-20